JP2016540000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540000A5 JP2016540000A5 JP2016538587A JP2016538587A JP2016540000A5 JP 2016540000 A5 JP2016540000 A5 JP 2016540000A5 JP 2016538587 A JP2016538587 A JP 2016538587A JP 2016538587 A JP2016538587 A JP 2016538587A JP 2016540000 A5 JP2016540000 A5 JP 2016540000A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- use according
- dioxolo
- piperazin
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3- {4- [4- (8-oxo-8H- [1,3] dioxolo [4,5-g] chromen-7-yl) -butyl] -piperazin-1-yl} -phenyl Chemical group 0.000 claims 5
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003997 social interaction Effects 0.000 claims 2
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 claims 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 1
- 101800000989 Oxytocin Proteins 0.000 claims 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- ZPPHFUACQVCJTO-UHFFFAOYSA-N [1,3]dioxolo[4,5-g]chromen-8-one Chemical compound C1=C2C(=O)C=COC2=CC2=C1OCO2 ZPPHFUACQVCJTO-UHFFFAOYSA-N 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- 229960000794 baclofen Drugs 0.000 claims 1
- NWPJLRSCSQHPJV-UHFFFAOYSA-N carpipramine Chemical compound C1CN(CCCN2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 NWPJLRSCSQHPJV-UHFFFAOYSA-N 0.000 claims 1
- 229960000700 carpipramine Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 1
- 229960001723 oxytocin Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306726.4 | 2013-12-13 | ||
| EP13306726 | 2013-12-13 | ||
| PCT/EP2014/077635 WO2015086836A1 (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540000A JP2016540000A (ja) | 2016-12-22 |
| JP2016540000A5 true JP2016540000A5 (enExample) | 2018-02-01 |
| JP6419826B2 JP6419826B2 (ja) | 2018-11-07 |
Family
ID=49883003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538587A Expired - Fee Related JP6419826B2 (ja) | 2013-12-13 | 2014-12-12 | 自閉症スペクトラム障害の治療のためのドーパミンｄ３受容体拮抗薬としてのクロモン誘導体 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10028948B2 (enExample) |
| EP (1) | EP3079688B1 (enExample) |
| JP (1) | JP6419826B2 (enExample) |
| KR (1) | KR102280530B1 (enExample) |
| CN (1) | CN105792824B (enExample) |
| AU (1) | AU2014363428B2 (enExample) |
| BR (1) | BR112016012552A8 (enExample) |
| CA (1) | CA2932791C (enExample) |
| CY (1) | CY1119907T1 (enExample) |
| DK (1) | DK3079688T3 (enExample) |
| ES (1) | ES2657706T3 (enExample) |
| HR (1) | HRP20180323T8 (enExample) |
| HU (1) | HUE036035T2 (enExample) |
| IL (1) | IL245996B (enExample) |
| LT (1) | LT3079688T (enExample) |
| MA (1) | MA39076A1 (enExample) |
| MX (1) | MX372922B (enExample) |
| MY (1) | MY172937A (enExample) |
| NO (1) | NO3079688T3 (enExample) |
| NZ (1) | NZ720868A (enExample) |
| PL (1) | PL3079688T3 (enExample) |
| PT (1) | PT3079688T (enExample) |
| RS (1) | RS56931B1 (enExample) |
| RU (2) | RU2019104946A (enExample) |
| SA (1) | SA516371298B1 (enExample) |
| SI (1) | SI3079688T1 (enExample) |
| TN (1) | TN2016000213A1 (enExample) |
| UA (1) | UA117271C2 (enExample) |
| WO (1) | WO2015086836A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2975A (en) | 2008-07-16 | 2014-09-30 | Richter Gedeon Nyrt | Pharmaceutical formulations containing dopamine receptor ligands |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| GB2604247B (en) * | 2019-09-11 | 2025-07-02 | Oxford BioDynamics PLC | Diagnostic chromosome marker |
| KR20220021157A (ko) | 2020-08-13 | 2022-02-22 | 원광대학교산학협력단 | 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2682953B1 (fr) * | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
| DE4229880A1 (de) * | 1992-09-04 | 1994-03-31 | Knauf Siegfried | Medikament bzw. Medikamentenzusammensetzung |
| SK4782001A3 (en) | 1998-10-08 | 2001-11-06 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| US8461148B2 (en) * | 2004-09-20 | 2013-06-11 | Icahn School Of Medicine At Mount Sinai | Use of memantine (namenda) to treat autism, compulsivity and impulsivity |
| EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
| FR2949465B1 (fr) | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| KR101921772B1 (ko) * | 2011-05-13 | 2018-11-23 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 장치 |
| FR2976179A1 (fr) * | 2011-06-09 | 2012-12-14 | Pf Medicament | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |
-
2014
- 2014-12-12 EP EP14812465.4A patent/EP3079688B1/en not_active Not-in-force
- 2014-12-12 SI SI201430603T patent/SI3079688T1/en unknown
- 2014-12-12 TN TN2016000213A patent/TN2016000213A1/en unknown
- 2014-12-12 MX MX2016007612A patent/MX372922B/es active IP Right Grant
- 2014-12-12 ES ES14812465.4T patent/ES2657706T3/es active Active
- 2014-12-12 CA CA2932791A patent/CA2932791C/en active Active
- 2014-12-12 LT LTEP14812465.4T patent/LT3079688T/lt unknown
- 2014-12-12 WO PCT/EP2014/077635 patent/WO2015086836A1/en not_active Ceased
- 2014-12-12 BR BR112016012552A patent/BR112016012552A8/pt not_active Application Discontinuation
- 2014-12-12 US US15/103,470 patent/US10028948B2/en active Active
- 2014-12-12 HR HRP20180323TT patent/HRP20180323T8/hr unknown
- 2014-12-12 RU RU2019104946A patent/RU2019104946A/ru unknown
- 2014-12-12 PT PT148124654T patent/PT3079688T/pt unknown
- 2014-12-12 UA UAA201607311A patent/UA117271C2/uk unknown
- 2014-12-12 MY MYPI2016702136A patent/MY172937A/en unknown
- 2014-12-12 JP JP2016538587A patent/JP6419826B2/ja not_active Expired - Fee Related
- 2014-12-12 DK DK14812465.4T patent/DK3079688T3/da active
- 2014-12-12 PL PL14812465T patent/PL3079688T3/pl unknown
- 2014-12-12 NO NO14812465A patent/NO3079688T3/no unknown
- 2014-12-12 RS RS20180196A patent/RS56931B1/sr unknown
- 2014-12-12 KR KR1020167015313A patent/KR102280530B1/ko not_active Expired - Fee Related
- 2014-12-12 RU RU2016125829A patent/RU2686110C1/ru active
- 2014-12-12 NZ NZ720868A patent/NZ720868A/en not_active IP Right Cessation
- 2014-12-12 AU AU2014363428A patent/AU2014363428B2/en not_active Ceased
- 2014-12-12 CN CN201480066587.4A patent/CN105792824B/zh not_active Expired - Fee Related
- 2014-12-12 HU HUE14812465A patent/HUE036035T2/hu unknown
- 2014-12-12 MA MA39076A patent/MA39076A1/fr unknown
-
2016
- 2016-06-02 IL IL245996A patent/IL245996B/en active IP Right Grant
- 2016-06-12 SA SA516371298A patent/SA516371298B1/ar unknown
-
2018
- 2018-02-09 CY CY20181100159T patent/CY1119907T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015534562A5 (enExample) | ||
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| JP2013520405A5 (enExample) | ||
| JP2015083580A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| PH12016501439A1 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| GT201600142A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
| JP2015525757A5 (enExample) | ||
| RU2014149181A (ru) | Производное пиразола и его применение в медицинских целях | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| WO2016109217A3 (en) | Btk inhibitors | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2013533867A5 (enExample) | ||
| HRP20180323T1 (hr) | Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| MX2015014672A (es) | Composicion farmaceutica oral para prevenir o tratar el sindrome de ojo seco que comprende rebamipida o un profarmaco de la misma. | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2017515840A5 (enExample) | ||
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| CO6592109A2 (es) | Nueva forma cristalina de un derivado de ciclopropilbenzamida | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии |